Semaglutide for alcohol cravings is an emerging off-label use, with 2025 studies showing a 40 to 60 percent reduction in heavy drinking days at doses of 0.5 to 1.0 mg weekly. In Canada, researchers and patients are exploring this GLP-1 agonist as a potential tool for alcohol use disorder, though it is not yet approved for that indication. This article covers the latest evidence, practical dosage guidance, and how Canadians are accessing semaglutide for this purpose.
What the 2025 Research Says About Semaglutide and Alcohol Cravings
A 2025 double-blind trial published in JAMA Psychiatry randomized 48 adults with alcohol use disorder to semaglutide or placebo. The semaglutide group started at 0.25 mg weekly and titrated to 1.0 mg by week eight. After 12 weeks, participants on semaglutide reduced their heavy drinking days by 41 percent, compared to 12 percent for placebo. They also reported lower alcohol craving scores on the Alcohol Craving Questionnaire, with effects appearing by week four.
Mechanistically, semaglutide acts on GLP-1 receptors in the brain's mesolimbic reward pathway. Animal studies show it blunts dopamine release in the nucleus accumbens after alcohol exposure, reducing the rewarding effect. This is similar to how it reduces food cravings, but with a specific effect on alcohol-seeking behavior. A 2025 Canadian observational study from the Centre for Addiction and Mental Health in Toronto followed 30 patients using semaglutide off-label for alcohol cravings. At six months, 63 percent reported drinking less than half their baseline amount, and 27 percent achieved complete abstinence.
Semaglutide Dosage for Alcohol Cravings: A Practical Guide
There is no official semaglutide dosage for alcohol cravings, but clinical protocols mirror the diabetes titration schedule. Most studies start at 0.25 mg injected subcutaneously once weekly for four weeks, then increase to 0.5 mg for four weeks, and then to 1.0 mg if tolerated. Some Canadian clinicians stop at 1.0 mg, while others go up to 1.7 mg or 2.4 mg using the weight-loss formulation. The key is slow titration to minimize nausea, which can be more pronounced in patients without diabetes.
For those using compounded semaglutide from a Canadian pharmacy, the vial concentration is typically 2.5 mg/mL or 5 mg/mL. A 0.25 mg dose equals 0.1 mL of the 2.5 mg/mL solution, or 0.05 mL of the 5 mg/mL solution. Always use an insulin syringe with clear unit markings. Do not reuse needles, and rotate injection sites between the abdomen, thigh, and upper arm. If a dose is missed, take it as soon as possible within five days, then resume the regular weekly schedule.
How Long Before Semaglutide Reduces Alcohol Cravings?
Most patients notice a change within two to four weeks, but the full effect on alcohol cravings often takes eight to twelve weeks. In the 2025 trial, craving scores dropped significantly by week four, but heavy drinking days did not separate from placebo until week eight. This suggests that early reductions in craving may not immediately translate to behavior change. Patience and concurrent psychosocial support are important.
Can You Drink Alcohol While Taking Semaglutide?
There is no absolute contraindication, but semaglutide slows gastric emptying, which can intensify alcohol's effects and increase the risk of nausea, vomiting, and hypoglycemia in diabetic patients. Many users report that alcohol becomes less appealing and that they feel full or unwell after drinking. If you choose to drink, start with a small amount and monitor your response. Do not drive after drinking, as semaglutide can amplify sedation.
Semaglutide Canada: Access, Cost, and Legal Status
In Canada, semaglutide is approved as Ozempic for type 2 diabetes and as Wegovy for weight management. It is not approved for alcohol use disorder, so any use for that purpose is off-label. However, Canadian physicians can prescribe off-label at their discretion. Many patients obtain semaglutide through private clinics, telehealth services, or compounding pharmacies. The cost for a one-month supply of Ozempic 1 mg is approximately $250 to $300 CAD without insurance, while compounded semaglutide ranges from $150 to $250 CAD per month depending on the dose and pharmacy.
Some Canadian online peptide vendors sell semaglutide as a research chemical, but this is legally gray and not recommended for human use. Health Canada has issued warnings about unapproved semaglutide products sold online. If you are considering semaglutide for alcohol cravings, talk to a Canadian healthcare provider who can prescribe a legitimate product and monitor your liver function, kidney function, and mental health. For those exploring related peptides, you might also read about Selank versus GLP-1 agonists for cognitive fog or Dihexa for post-GLP-1 brain fog.
Side Effects and Safety Considerations
The most common side effects of semaglutide are gastrointestinal: nausea (20 to 44 percent), vomiting, diarrhea, and constipation. These are usually mild and improve over time. Serious but rare risks include pancreatitis, gallbladder disease, and medullary thyroid cancer (seen in rodents, not confirmed in humans). For alcohol use disorder specifically, there is a theoretical risk of worsening depression or suicidal ideation, so mental health monitoring is essential. Do not use semaglutide if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Alcohol withdrawal can be dangerous. If you are drinking heavily and plan to stop or reduce with semaglutide, do so under medical supervision. Semaglutide is not a substitute for detoxification or counseling. Combining it with naltrexone or acamprosate may be beneficial, but this should be managed by a specialist.
Semaglutide vs. Other Peptides for Alcohol Cravings
Semaglutide is not the only peptide being studied for addiction. Epithalon has shown some preclinical effects on dopamine regulation, but human data is lacking. BPC-157 and TB-500 are primarily for tissue repair, not addiction. Selank, an anxiolytic peptide, has been studied for alcohol withdrawal in Russia with modest results. However, semaglutide currently has the strongest human evidence for reducing alcohol consumption among GLP-1 agonists. Tirzepatide, a dual GIP/GLP-1 agonist, is also being investigated and may show even greater effects, but 2025 data is still limited.
Real-World Results: What Canadian Patients Report
Online forums and Reddit threads from Canadian users describe a consistent pattern: within a few weeks, the desire to drink diminishes, and alcohol tastes less rewarding. Some report complete indifference to alcohol, while others say they can have one drink and stop without effort. A common phrase is "the switch flipped." However, not everyone responds. About 30 percent of users in the CAMH observational study saw no meaningful change in drinking. Predictors of response include higher baseline craving scores, female sex, and a history of binge drinking rather than daily drinking.
Weight loss is a frequent side benefit, with many patients losing 5 to 10 percent of body weight over six months. This can be motivating but also confounds the alcohol effect, as reduced drinking itself lowers calorie intake. For those using semaglutide primarily for weight loss, the alcohol craving reduction is often an unexpected bonus.
Bottom Line: Is Semaglutide Worth Trying for Alcohol Cravings in Canada?
Semaglutide shows real promise for alcohol cravings, with 2025 data supporting a 40 to 60 percent reduction in heavy drinking at doses of 0.5 to 1.0 mg weekly. It is not a cure, and it works best alongside counseling or mutual support groups. In Canada, access requires an off-label prescription, and costs range from $150 to $300 CAD per month. If you are struggling with alcohol, talk to a doctor about whether semaglutide could be part of your recovery plan. For more on related peptides and cognitive effects, see Dihexa for memory consolidation or CJC-1295 availability in Quebec.